Global Drug-Eluting Balloon Catheters Market Strategic Research Report

Scope of the Report

The global Drug-Eluting Balloon Catheters market size is predicted to grow from US$ 1,487 million in 2025 to US$ 3,521 million in 2032; it is expected to grow at a CAGR of 13.0% from 2026 to 2032.

Drug-eluting balloon catheters (often referred to as drug-coated balloon catheters, DCB) are endovascular angioplasty balloons coated with an antiproliferative drug plus an excipient/carrier system. During angioplasty, they deliver mechanical lumen gain while rapidly transferring drug into the vessel wall to inhibit neointimal hyperplasia and reduce restenosis and repeat interventions. The strategic concept is “leave nothing behind,” avoiding the long-term burden of permanent implants and enabling flexible future treatment options, increasingly integrated with lesion-preparation tools and intravascular imaging to support more refined vascular repair.In 2025, global Drug-eluting balloon catheters production reached approximately1528 k units and price is 995 USD/Unit.The average gross profit margin of this product is 73%.

Growth is driven by two structural forces: a shift from implant-centric to repair-centric care, where DCBs address restenosis and reintervention pain points with a “leave nothing behind” proposition; and a clearer evidence/regulatory boundary that improves hospital-level adoption confidence. The FDA’s updated assessment on paclitaxel-coated devices for PAD strengthens predictability around long-term safety considerations. Meanwhile, leading medtech companies continue to position DCB portfolios as a contributor to peripheral/vascular growth in annual reporting, signaling an evolution from an adjunct option toward a more standardized toolset.

The hurdle is scaling with reproducibility and compliance. As drug-device combination products, DCBs are highly sensitive to coating integrity, particulate control, dose consistency, and stability—where process drift can translate into outsized clinical and access risk. In parallel, cost containment and procurement reforms elevate quality systems, supply assurance, and cost efficiency as decisive differentiators. In China, national-level centralized procurement and published outcomes accelerate a more rules-based, scale-driven competitive phase.

Demand is consolidating around repeatable techniques and bundled solutions. Hospitals increasingly prioritize lower repeat interventions, pathway efficiency, and stable long-term outcomes—driving more routine combination of DCBs with lesion preparation tools, specialty balloons, and intravascular imaging (IVUS/OCT). In peripheral and dialysis access settings where recurrence is common, the preference to avoid repeat implants and preserve future options further reinforces the “leave nothing behind” value narrative.

Upstream advantage is defined by integrated “materials-coating-validation” capability rather than a simple bill of materials. Key inputs include balloon/catheter polymers and reinforcements, drug APIs (paclitaxel or limus agents) and excipient systems, coating solvents and metrology consumables, lubricious/hydrophilic surface coatings, plus sterile barrier packaging and sterilization services. Because requirements on biocompatibility and change control are stringent, medical-grade traceability, clean manufacturing, and robust change management at the supplier level directly shape yield, release consistency, and global compliance efficiency for OEMs.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Drug-Eluting Balloon Catheters market?

What factors are driving Drug-Eluting Balloon Catheters market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Drug-Eluting Balloon Catheters market opportunities vary by end market size?

How does Drug-Eluting Balloon Catheters break out by Type, by Application?

This report presents a comprehensive overview of the global Drug-Eluting Balloon Catheters market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Coronary Artery Disease Drug-Eluting Balloon Catheters
• Peripheral Vascular Disease Drug-Eluting Balloon Catheters

Segment by Balloon Platform Mechanics

• Semi-/Compliant
• Non-compliant
• Other

Segment by Application

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Catheterization Laboratories

Segment by Application

• In-Stent Restenosi
• De Novo
• Small Vessel

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Drug-Eluting Balloon Catheters market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in In-Stent Restenosi, De Novo, Small Vessel evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact